HUTCHMED (CHINA) LIMITED - AMERICAN DEPOSITARY SHA

HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda

26 4 2024 07:30:00 提供 Nasdaq GlobeNewswire

HUTCHMED Highlights Data to be Presented at AACR Congress 2024

05 4 2024 03:30:00 提供 Nasdaq GlobeNewswire

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

01 4 2024 23:30:00 提供 Nasdaq GlobeNewswire

HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

27 3 2024 19:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

21 3 2024 19:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Reports 2023 Full Year Results and Provides Business Updates

28 2 2024 05:30:00 提供 Nasdaq GlobeNewswire

HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session

06 2 2024 18:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership

02 2 2024 02:30:00 提供 Nasdaq GlobeNewswire

HUTCHMED to Announce 2023 Final Results

01 2 2024 02:30:00 提供 Nasdaq GlobeNewswire

HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer

29 1 2024 22:53:49 提供 Nasdaq GlobeNewswire

HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status

10 1 2024 18:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at Current Terms

12 12 2023 22:30:00 提供 Nasdaq GlobeNewswire

HUTCHMED Announces that it has Completed Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China

12 12 2023 18:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology Congresses

30 11 2023 18:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

08 11 2023 18:11:18 提供 Nasdaq GlobeNewswire

HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2023

16 10 2023 03:30:00 提供 Nasdaq GlobeNewswire

HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

29 9 2023 03:30:00 提供 Nasdaq GlobeNewswire

HUTCHMED Highlights Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer

12 9 2023 03:30:00 提供 Nasdaq GlobeNewswire

HUTCHMED Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China

11 9 2023 19:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer

28 8 2023 19:00:00 提供 Nasdaq GlobeNewswire